Search

Displaying results 1211 - 1220 of 4207 in total
  1. Drug

    Etranacogene dezaparvovec

    go.drugbank.com/drugs/DB16791
    ApprovedInvestigational

    [L45255] Etranacogene dezaparvovec was approved by the EMA in February 2023[L45439,L45444] and by Health Canada in October 2023.[L48801] … [L44156] Etranacogene dezaparvovec was approved by the FDA in November 2022 for the treatment of select patients with hemophilia B, becoming the first gene therapy approved for this indication.

  2. Drug

    Eletriptan

    go.drugbank.com/drugs/DB00216
    ApprovedInvestigational

    Eletriptan is a second generation triptan drug developed by Pfizer Inc for the treatment of migraine headaches.

  3. Drug

    Islatravir

    go.drugbank.com/drugs/DB15653
    ApprovedInvestigational

    [A275492, L56138] Chemically, it is a deoxyadenosine analogue distinguished by a 4'-ethynyl group and a 2-fluoro substitution, which collectively enhance its metabolic stability and potency. … [A275490, A275492] Because it is a substrate for deoxycytidine kinase (dCK), its efficacy can be compromised by co-administration with other dCK substrates like lamivudine or emtricitabine, which are consequently

  4. Drug

    Cinnamyl alcohol

    go.drugbank.com/drugs/DB14186
    Approved

    Cinnamyl alcohol is a naturally occurring compound that is found within cinnamon. Due to the low levels found in cinnamon, cinnamyl alcohol is usually supplied as DB14184 within commercial products. Cinnamyl alcohol has been shown to be ...

  5. Drug

    Alprazolam

    go.drugbank.com/drugs/DB00404
    ApprovedIllicitInvestigational

    [L34783, L34788] It is mainly metabolized by CYP3As and so is contraindicated with CYP3A inhibitors like ketoconazole and itraconazole. … [L34783, L34788] Benzodiazepine treatment should be stopped gradually by tapering down a patient's dose to avoid withdrawal symptoms.

  6. Drug

    Benzgalantamine

    go.drugbank.com/drugs/DB19353
    ApprovedInvestigational

    [L51564] Benzgalantamine was approved by the FDA in July 2024 for the treatment of mild-to-moderate dementia in Alzheimer's patients.[L51534,L51564]

  7. Drug

    Flortaucipir F-18

    go.drugbank.com/drugs/DB14914
    ApprovedInvestigational

    It was approved by the FDA on May 28, 2020, for sale by Avid Radiopharmaceuticals under the name TAUVID™ and is the first FDA-approved molecule for imaging aggregated tau protein in the brain.[L14114]

  8. Drug

    Avalglucosidase alfa

    go.drugbank.com/drugs/DB16099
    ApprovedInvestigational

    [L35160] Avalglucosidase alfa was approved by Health Canada on November 15, 2021 for the treatment of patients older than six months of age with late-onset Pompe disease. … Avalglucosidase alfa, or NeoGAA, is a drug for enzyme replacement therapy specifically designed for Pompe disease, a rare inherited neuromuscular disorder caused by the deficiency of the alpha-glucosidase

  9. Drug

    Butamben

    go.drugbank.com/drugs/DB11148
    ApprovedWithdrawn

    [A27147] Its structure corresponds to the standard molecule of a hydrophilic and hydrophobic domain separated by an intermediate ester found in most of the local anesthetics.

  10. Drug

    Niraparib

    go.drugbank.com/drugs/DB11793
    ApprovedInvestigational

    [L43277] Niraparib was approved by the European Commission on November 16, 2017 [L43742] and by Health Canada on June 27, 2019. … By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells.[L43277] Niraparib is selective towards PARP-1 and PARP-2.